| Literature DB >> 34066896 |
Marc Hernaiz-Llorens1, Ramón Martínez-Mármol2, Cristina Roselló-Busquets1, Eduardo Soriano1,3.
Abstract
Central nervous system damage caused by traumatic injuries, iatrogenicity due to surgical interventions, stroke and neurodegenerative diseases is one of the most prevalent reasons for physical disability worldwide. During development, axons must elongate from the neuronal cell body to contact their precise target cell and establish functional connections. However, the capacity of the adult nervous system to restore its functionality after injury is limited. Given the inefficacy of the nervous system to heal and regenerate after damage, new therapies are under investigation to enhance axonal regeneration. Axon guidance cues and receptors, as well as the molecular machinery activated after nervous system damage, are organized into lipid raft microdomains, a term typically used to describe nanoscale membrane domains enriched in cholesterol and glycosphingolipids that act as signaling platforms for certain transmembrane proteins. Here, we systematically review the most recent findings that link the stability of lipid rafts and their composition with the capacity of axons to regenerate and rebuild functional neural circuits after damage.Entities:
Keywords: CNS injury; axonal growth-inhibitory molecules; axonal regeneration; cholesterol; lipid rafts; neurodegeneration; sphingolipid
Year: 2021 PMID: 34066896 PMCID: PMC8125918 DOI: 10.3390/ijms22095009
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Schematic representation of a lipid bilayer of a cell membrane depicting lipid raft-associated proteins (green) and transmembrane proteins (yellow) excluded from these domains. Lipid rafts are membrane fractions enriched in cholesterol (red) and sphingolipids (blue), as well as harboring GPI-anchored proteins (light blue).
Methodologies used to study lipid-raft-associated proteins.
| Method | Type | Description | References |
|---|---|---|---|
| Membrane fractionation | Biochemical | Solubilization of lipids and membrane proteins | [ |
| Cholera Toxin B-subunit | Selective probe for membrane microdomains | Specifically binding to GM1 | [ |
| Laurdan | Environmentally sensitive fluorescence probe | Photoshifting between lipid-ordered and -disordered phases | [ |
| Giant unilamellar vesicles | Artificial model membrane | Behavior of different lipid species | [ |
| Fluorescence Recovery After Photobleaching (FRAP) | Biophysical | Study of lateral mobility of photolabeled proteins | [ |
| Super-resolution microscopy | Biophysical | Visualization of molecules beyond the diffraction limit | [ |
| Fluorescence Resonance Energy Transfer (FRET) | Biophysical | Visualization of dynamic signaling events at membrane microdomains | [ |
Figure 2Lipid raft-dependent inhibitory axonal growth signaling of guidance cues and their receptors. (A) Axonal growth inhibition exerted by Netrin occurs in the presence of UNC5 receptors, either when bound to UNC5 alone or when heterodimerizing with the DCC receptor. Ig: Immunoglobulin domain (green); TSPI: Thrombospondin type I domain (blue); ZU5: Zona Occludens (light blue); DB: DCC-binding domain (yellow); DD: Death Domain (red); FNIII: Fibronectin type III domain (light blue); EGF: Epidermal Growth Factor repeats (gray). (B) Eph transmembrane receptors bind to both, GPI-anchored ephrinA or ephrinB, resulting in contact-mediated repulsion. PDZ: Postsynaptic Density 95-Discs large-Zonula occludens-1-protein (purple); SAM: Sterile Alpha Motif (yellow). (C) Semaphorin first interacts with the NRP receptors, which is the initial step for a receptor complex assembly. Transmembrane Semaphorins are also recognized by plexins, which are their binding receptor. PSI: Plexin-Sema-Integrin domain (gray); CUB: Complement-like domain (blue); CF V/VIII: V/VIII Clotting Factor domain (red); MAM: Meprin-like domain (orange); IPT: Immunoglobin-like fold shared by plexins and transcription factors (blue); GAP: GTPase Activating Protein domain (yellow); RBD: Rho-binding domain (purple). (D) Slit is able to bind the Robo receptor, which in turn inactivates intracellular machinery blocking the axonal extension. In the presence of both Slit and Netrin, the Robo and the DCC receptors interact, causing the inhibition of chemoattraction expected by the Netrin-DCC pair. Heparan sulfate chains are co-receptors for Robo and Slit, which stabilize the Slit-Robo complex, resulting in axonal repulsion.
Lipid raft destabilizing agents.
| Agent | Type | Mechanism | References |
|---|---|---|---|
| Cyclodextrins | Cyclic oligosaccharides | Cell membrane cholesterol depletion | [ |
| Statins | HMG-CoA inhibitor | Cholesterol biosynthesis inhibition | [ |
| Cholesterol Oxidase | Enzymatic flavoprotein | Cholesterol oxidation | [ |
| Filipins | Polyene macrolides | Cell membrane cholesterol sequestration | [ |
| Apolipoprotein A-I Binding Protein | Protein encoded by the | Cholesterol efflux promotion | [ |
| Triparanol | Δ7-Reductase inhibitor | Cholesterol biosynthesis inhibition | [ |
| Glycophosphatidylinositol-specific Phospholipase C | Enzymatic phospholipase | Cleaving of GPI-anchored surface proteins | [ |
| Overexpression of Cyp46A1 | Cholesterol-catabolic enzyme | Cholesterol conversion to (24S)-24-hydroxycholesterol | [ |
| Fumonisin B1 | Sphingolipid synthesis inhibitor | Synthesis inhibition of dihydroceramide | [ |
Studies of cholesterol-lowering drugs in axonal regeneration models.
| Compound | Model | Effect | References |
|---|---|---|---|
| MβCD and ChOx | Temporal explants (in vitro) | Axonal growth on inhibitory RGMa substrate | [ |
| MβCD | Axotomized retinal ganglion cells (in vivo) | Neogenin-dependent apoptosis blocking | [ |
| MβCD | SCI (in vivo) | Motor functional recovery | [ |
| Lovastatin | Optic nerve injury (in vivo) | Regeneration and axonal sprouting | [ |
| Prominin-1 overexpression | Cultured DRG neurons (in vitro) | Enhanced axonal regeneration | [ |
| Statins | Spinal motor neurons (in vitro) | Axonal growth on inhibitory substrates | [ |
| Cerivastatin | Optic nerve injury (in vivo) | Regeneration of retinal ganglion cell axons | [ |
| MβCD, ChOx and Nystatin | CNS and PNS developing neurons (in vitro) | Increased growth cone area, density of filopodium-like structures and the number of neurites branching points | [ |
| Nystatin | Axotomized hippocampal neurons in a microfluidic chamber (in vitro) | Increased axonal regeneration | [ |
| Nystatin | Axotomized entorhinal-hippocampal projection in organotypic culture (ex vivo) | Increased axonal regeneration | [ |
| MβCD | Sciatic nerve injury (in vivo) | Axonal regeneration and functional recovery | [ |
| 2-hydroxypropyl-β-cyclodextrin | SCI (in vivo) | Increased axon regeneration | [ |